Cardiovascular devices cover a broad range of indications and forms, from access catheters to heart valves. Their use directly in the vascular system means that the safe design and validation of these devices is of particular importance for patient safety. Cambridge Polymer Group supports cardiovascular device companies that need clear, defensible answers about their materials, assemblies, and failure modes, as well as in development, validation and regulatory testing of new materials and devices. We help you understand the complex behavior of polymers and how they evolve through processing, sterilization, and use, so you can reduce late‑stage surprises, manage devices across their lifecycle with greater confidence and maximize safety for the patient.

Who CPG Supports in Cardiovascular Product and Failure Decisions

We work with teams responsible for a wide range of roles through the product lifecycle. Often these teams are responsible for setting cardiovascular product and R&D direction or managing the development of invasive and blood‑contacting devices, as well as teams actively involved in selecting materials and designing devices. We also frequently support teams ensuring manufacturing, cleaning and sterilization are effective and robust. We also support leaders who need to clearly explain material choices, risks, and validation strategies to internal stakeholders, investors, partners, and regulators.

Many organizations come to CPG when a critical device has failed and the root cause is unclear. Here out broad experience can help fast-track root-cause determination and mitigation release holds on product impacting schedules. Companies also approach us when they must design ISO 10993‑18 chemical characterization that is rigorous but not excessive, tailored with the specific use-case and material in mind. We have also assisted when companies are qualifying new tubing, resins, coatings, or hydrogels under specific sterilization and aging conditions, or qualifying second-source suppliers. If you recognize these situations, the capabilities outlined below are built to address them directly.

Materials Used in Cardiovascular Devices

Cardiovascular devices depend on combinations of polymers, metals, and fluids that must perform reliably together under demanding conditions. CPG works extensively with:

  • Fluoropolymers, urethanes, EVOH, PET, polycarbonates, polyethylenes, silicones, and other medical‑grade polymers used in devices such as catheters, guidewires, stents, balloons, and blood‑handling kits
  • Tubing for catheters, pumps, and accessories, including wall thickness, concentricity, flexibility, bondability, and dimensional stability
  • Radiopaque formulations in catheters, guidewires, and stents, where imaging visibility must be balanced against flexibility and fatigue resistance
  • Hydrogels and natural polymers such as chitosan used in delivery systems and tissue‑interactive components
  • Injectable and implantable materials used for sensors, tissue bulking or spacing, drug release and more.

Our work helps pick the right material for the precise indication in the context of regulatory demands or validate the correct material has been selected for the desired end-use. We also illuminate whether observed behavior, such as variation in tubing performance, changes after sterilization, or unexpected surface appearance, can be attributed to material choice, processing, geometry, sterilization, or aging, and how those factors can be brought under better control in specifications and processes.

Analytical Testing that Informs Decisions

To understand material behavior and changes over time, we apply analytical methods selected to answer specific questions rather than as a generic panel. Common techniques include:

  • DSC (Differential Scanning Calorimetry): Evaluates glass transition, melting behavior, and crystallinity, supporting process‑window definition, weld assessment, and comparisons before and after sterilization or accelerated aging.
  • TGA (Thermogravimetric Analysis): Measures thermal stability, filler content, and degradation onset, helping differentiate formulations and detect early breakdown.
  • GPC (Gel Permeation Chromatography): Quantifies molecular weight and molecular‑weight distribution in resins and finished parts, enabling inter‑lot assessments, resin parameter verification, and evaluation of degradation due to processing or radiation.
  • LCMS, GCMS and related techniques: Support ISO 10993‑18 chemical characterization, extractables and leachables programs, cleaning validation, and validation of sterilant solutions for cardiovascular systems.
  • Accelerated aging: Thermal aging and OIT (Oxidative Induction Time) provide insight into oxidative stability and antioxidant behavior, which can be linked to sterilization and accelerated aging strategies.
  • SEM (Scanning Electron Microscopy) and surface imaging: Reveal fracture features, surface morphology, coating integrity, and local damage in polymers and metal–polymer interfaces.
  • Friction, lubrication and surface energy: Guidewire and catheter motion and steerability, the impact of surface finish and coating, changes due to biofouling or tissue response.

Together, these methods help answer questions such as why certain lots perform differently, how sterilization or storage is affecting materials, and which changes matter most for device function and risk.

Device‑Level Failure Analysis and Root‑Cause Investigations

Many critical issues only become apparent at the assembled device level. CPG evaluates finished and returned cardiovascular devices to determine why they failed and to outline practical options for remediation. Typical components and situations include:

  • Balloons with localized pinholes, thin‑wall defects, fatigue tearing or weld‑zone concerns
  • Stents exhibiting signs of fatigue, degradation, or surface changes
  • Catheter and tubing systems with kinks, fractures, voids or bond failures
  • Metal components including jaws, clip mechanisms, and nitinol elements in surgical endoscopic applicators and cardiovascular delivery systems.
  • Coatings and surfaces on guidewires, catheters, and blood‑handling kits that show flaking, wear, or unexpected appearance or behavior.

Typical questions in failure analysis focus on whether a problem arises from resin properties, process conditions, component geometry, sterilization, aging, or a combination of these factors. We also examine if the specific physiological conditions may be driving the observed issue. The objective is to link what you see in testing or field returns, such as variability in tubing performance, changes after sterilization, or unexpected surface features, to specific, controllable parameters in specifications, processing, or design.

Investigations often combine SEM or optical review and fracture analysis with DSC, TGA, GPC, LCMS, OIT, and dimensional measurements as appropriate, but can often require more unusual tests to determine cause. This analysis is always more effective in close collaboration with the client. The result is a clear root‑cause narrative that distinguishes between design limitations, process drift, material variability, and the impact of sterilization or aging, and that can be used to support internal reviews and external communication.

ISO 10993‑18 Chemical Characterization, Cleaning, and Sterilization

Cardiovascular devices are held to high standards around chemical risk, cleanliness, and sterilization. CPG designs and executes ISO 10993‑18‑aligned chemical characterization programs that:

  • Identify and quantify extractables and leachables from polymers, coatings, adhesives, process aids, and packaging
  • Support cleaning validation efforts and the validation of sterilant solutions for blood‑handling kits, catheters, and related accessories
  • Integrate chemical characterization results into broader biological evaluation and risk‑management frameworks

We also assess how sterilization modalities (such as gamma, e‑beam, and EtO) and radiation exposure affect polymers and hydrogels. These studies evaluate potential reaction byproducts, and their toxicological impact, as well as changes in molecular weight, crystallinity, appearance, and mechanical properties, and are often paired with accelerated aging to relate chemical changes to long‑term performance and shelf‑life. For operations and quality teams, this work helps reduce scrap and rework, avoid unexpected variability between lots, and lower the likelihood of repeat testing or post‑market investigations tied to materials and processing.

Case Studies in Cardiovascular Devices

Cambridge Polymer Group has supported a wide range of cardiovascular and implantable device projects. Representative case studies include:

  • Injectable Hydrogels for Tissue Bulking – Designed and characterized injectable hydrogel systems tuned for tissue bulking performance, handling, and stability under clinically relevant conditions.
  • Failure Analysis in Catheters – Investigated mechanical and material‑driven catheter failures, linking resin properties, processing conditions, and geometry to observed kinks, fractures, and bond issues.
  • Radiopacity of Medical Implants – Optimized radiopaque formulations for catheters and implants to balance imaging visibility with flexibility and fatigue resistance.
  • Biocompatibility [for Cardiovascular Devices] – Supported [cardiovascular] device teams in developing ISO 10993‑18 chemical characterization strategies and interpreting extractables and leachables data to support biological evaluation and risk management.

These case studies illustrate how we translate polymer science, analytical testing, and failure analysis into concrete decisions about materials, design, and processing for cardiovascular products.

How Cardiovascular Projects Proceed with CPG

Our goal is to provide structure, speed, and clear options rather than open‑ended testing. A typical engagement follows these stages:

  1. Initial discussion: We review the device type, observed failures or open questions, timelines, and key decisions that need to be supported.
  2. Focused work plan: We propose a prioritized set of analyses—such as SEM fracture analysis, DSC, TGA, GPC, LCMS, OIT, tubing characterization, and accelerated aging—with defined decision points and timelines.
  3. Initial findings: For many focused investigations, interpreted results and options can be provided within a few weeks, highlighting whether resin quality, design, processing, sterilization, or environment is the primary driver.
  4. Integration and follow‑up: We assist in translating findings into design modifications, supplier specifications, risk documentation, and manufacturing controls as needed.

Why Cardiovascular Organizations Choose Cambridge Polymer Group

Cardiovascular device programs depend on both technical performance and predictable progress through development, transfer, and post‑market phases. CPG contributes by:

  • Helping product and R&D leaders reduce the risk of material‑related issues emerging late in the development cycle
  • Providing development teams with technically rigorous but practical insights on polymers, hydrogels, tubing, coatings, and test methods
  • Enabling operations and quality groups to refine specifications, supplier expectations, and process controls to minimize material‑driven nonconformances
  • Supporting founders and executives with a clear, evidence‑based materials and testing narrative that can be communicated to investors, partners, auditors, and regulators

Whether you are working through a specific balloon, stent, catheter, or tubing issue, optimizing radiopacity in guidewires and delivery systems, or qualifying new materials and assemblies, Cambridge Polymer Group offers the polymer science and cardiovascular device experience needed to move forward with clarity.

If you are facing a materials or testing question on a cardiovascular device, contact Cambridge Polymer Group to review options.